Consensus AOCpKPIs – Results of a Modified Delphi Process
Took place Wednesday, November 27, 2024 at 12:00 PST, 13:00 MST, 14:00 CST, 15:00 EST, 16:00 AST
This webinar outlined the methodology used to develop a suite of 14 consensus KPIs for use in ambulatory oncology, including the definition, selection, and consensus processes employed. It also presented the consensus KPIs which were developed, and outlined next steps for implementation into oncology pharmacy practice.
Watch the Consensus AOCpKPIs – Results of a Modified Delphi Process webinar
Learning Objectives:
- Understand the Delphi consensus process
- Review the methodology used in defining, identifying and selecting candidate AOCpKPIs for inclusion
- Review results of the Delphi process and the finalized suite of consensus AOCpKPIs
- Outline the next steps and future directions for implementation of KPIs
Presented by Tom McFarlane and Lauren Hutton
Tom McFarlane is Clinical Lecturer and researcher at the University of Waterloo School of Pharmacy in Kitchener, Ontario, where he created, coordinates, and teaches the oncology portion of the curriculum in the Doctor of Pharmacy program. He is also an oncology pharmacist at North York General Hospital in Toronto, Ontario and has a primarily research-based cross-appointment at Odette Cancer Centre at Sunnybrook Health Sciences in Toronto.
Lauren Hutton is the Clinical Coordinator for Oncology Pharmacy at Nova Scotia Health - Central Zone. Lauren completed a BSc(Pharmacy) at Dalhousie University, her hospital residency at the Ottawa Hospital and subsequently went on to complete her PharmD at the University of Toronto. Lauren has been practicing in oncology for six years. Her oncology clinical practice areas have included ambulatory medical oncology, acute inpatient palliative oncology, and multiple myeloma ambulatory care. Lauren's current clinical practice is as an interdisciplinary member of a medical oncology team where she provides care to patients living with prostate cancer receiving treatment with oral anti-cancer therapy.
